Product Description
Mechanisms of Action: Gram+ Bacteria Inhibitor,Gram- Bacteria Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Bosnia | Bulgaria | Cyprus | Czech | Estonia | Germany | Greece | Hungary | India | Italy | Korea | Latvia | Lithuania | Luxembourg | Malta | New Zealand | Poland | Portugal | Romania | Russia | Serbia | Slovakia | Slovenia | Sweden | Switzerland | Turkey | Ukraine | United Arab Emirates
Approved Indications: None
Known Adverse Events: None
Company: Schülke & Mayr
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Catheter-Related Infections|Communicable Diseases|Bacteremia
Phase 3: Sepsis|Pharyngitis|Gingivitis
Phase 2: Healthy Volunteers|Gingivitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT06522438 | N/A |
Not yet recruiting |
Periodontal Pocket|Periodontitis|Periodontal Attachment Loss|Inflammation |
2025-10-01 |
|
2006-7041-83/hah | N/A |
Not yet recruiting |
Stroke |
2020-06-30 |
|
2017-001697-42 | P3 |
Completed |
Unknown |
2018-12-14 |
|
OML-III-A | P3 |
Completed |
Gingivitis |
2018-12-14 |
55% |